An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis

Osteoarthritis Clinical Trial

Official title:

A Randomized Controlled Trial on the Efficacy, Safety and Quality of Life Effects of Add-on Tramadol/Paracetamol Combination in Chronic Osteoarthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01728246
• Other study ID #: CR013696
• Secondary ID: TRAMAPNAP4002
• Status: Completed
• Phase: Phase 4
• First received: November 13, 2012
• Last updated: February 6, 2013
• Start date: October 2007
• Est. completion date: May 2008

Study information

• Verified date: February 2013
• Source: Janssen Pharmaceutica
• Contact: n/a
• Is FDA regulated: No
• Health authority: Philippines : Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety and effects on Quality of Life (QOL) of tramadol/paracetamol (APAP) as an add-on therapy (medication taken in addition to another medication) in Filipino participants with chronic (lasting a long time) osteoarthritis (disorder, which is seen mostly in older persons, in which the joints become painful and stiff).

Description:

This is an open-label (all people know the identity of the intervention), randomized (study drug assigned by chance), controlled study to evaluate the efficacy, safety and effects on QOL of tramadol/APAP as an add-on therapy in Filipino participants suffering from chronic pain because of chronic osteoarthritis. Participants will be randomly assigned to 2 groups: tramadol/APAP group and non tramadol/APAP group. Participants in tramadol/APAP group will receive celecoxib 200 milligram (mg) and fixed dose combination of tramadol (37.5 mg)/APAP (325 mg) as add on therapy, while the participants in non-tramadol/APAP group will receive celecoxib 200 mg only. The total duration of the study will be 4 weeks. The participants in both the groups will be given celecoxib 200 mg once daily for 4 weeks. In addition, the participants in the tramadol/APAP group will be given add-on tramadol/APAP doses 3 times a day for 4 weeks. Participants will be asked to return for follow-up at Weeks 2 and 4. Efficacy will be assessed using 100 millimeter (mm) Visual Analog Scale (VAS) while QOL will be assessed using the Oswestry Disability Index (ODI). Participant safety will be monitored throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 473
• Est. completion date: May 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with chronic osteoarthritis of knee or hip for greater than (>) or equal to (=) 1 year (based on the American College of Rheumatology (ACR) diagnostic criteria for osteoarthritis), who are experiencing at least moderate osteoarthritis pain (>=50 millimeter [mm] in 100 mm Visual Analog Scale [VAS])

• On any Cyclooxygenase - 2 (COX-2) inhibitors for at least 2 weeks preceding the study

• Women with childbearing potential must have negative pregnancy test

• Women of child bearing potential must agree to use accepted methods of contraception

• Participant has signed the written informed consent form

Exclusion Criteria:

• Participants taking Monoamine oxydase (MAO) inhibitors, neuroleptics or drugs for seizures

• Severe hepatic impairment (the impaired ability of the liver to fulfill its role in metabolism)

• On maintenance tramadol and/or paracetamol(APAP)

• On sedative hypnotics, short-acting analgesics, topical medications and anesthetics, and/or muscle relaxants

• Pregnant, lactating or breastfeeding participants

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoarthritis

Intervention

Drug:
• Tramadol/Paracetamol (APAP)
Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
• Non-Tramadol/APAP
Celecoxib 200 mg alone once daily for 4 weeks.

Locations

Country	Name	City	State
Philippines	Janssen Philippines	Paranaque City	Metro Manila

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Pharmaceutica

Country where clinical trial is conducted

Philippines, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) Score at Week 2	VAS is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.	Baseline and Week 2	No
Primary	Change From Baseline in VAS-pain Score at Week 4	VAS is a 100 mm scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain. Change=scores at observation minus score at Baseline. An increase in score from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.	Baseline and Week 4 Last Observation Carried Forward (LOCF)	No
Primary	Change From Baseline in Oswestry Disability Index (ODI) Score at Week 2	The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.	Baseline and Week 2	No
Primary	Change From Baseline in ODI Score at Week 4	The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). A higher score represents greater disability.	Baseline and Week 4 (LOCF)	No
Primary	Percentage of Participants Who Discontinued Because of Rescue Medication	Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.	Baseline up to Week 4	No
Primary	Time to Discontinuation Because of Rescue Medication	Rescue medications are medicines that may be administered to the participants when the efficacy of the study drug is not satisfactory, or the effect of the study drug is too great and is likely to cause a hazard to the participant, or to manage an emergency situation.	Baseline up to Week 4	No